Is Adjuvant Pembrolizumab Clinically Valuable?
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - The Lancet Oncology
Schema of the ACCIO trial including three arms. Pembrolizumab dosing is... | Download Scientific Diagram
Oncology Brothers on Twitter: "1. #KN091 #PEARLS by @peters_solange : Pembrolizumab in adjuvant settings and after chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA NSCLC. Approved for PDL1 expressions. -
Frühes nichtkleinzelliges Bronchialkarzinom: Pembrolizumab adjuvant nach Resektion verlängert das krankheitsfreie Überleben
Pembrolizumab in Metastatic Non–Small-Cell Lung Cancer | NEJM Resident 360
Stephen V Liu, MD on Twitter: "#ASCO22 Discussion of PEARLS (KEYNOTE-091, @ETOP_eu 8-15), a phase III study of adjuvant pembrolizumab in resected NSCLC. The study did meet its primary endpoint (DFS HR
ES/ONCO/1118/0300. - ppt download
Frontiers | Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone
The cutting-edge progress of immune-checkpoint blockade in lung cancer | Cellular & Molecular Immunology
Aakash Desai, MD, MPH on Twitter: "@LuisPaz_Ares discussed data from #PEARLS study #Pembrolizumab for early stage #NSCLC #LCSM with dual primary endpoint of DFS in all comers/PDL1>50%, showing significant DFS improvement HR:0.76
KURZPROTOKOLL PEARLS
Pembrolizumab in Early-Stage Non-Small Cell Lung Cancer After Complete Resection
Treatment benefits and outcome determinants in (neo)adjuvant trials - memoinOncology
FDA OKs Adjuvant Pembrolizumab for NSCLC | MedPage Today
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial | AIOM
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial | AIOM
PEARLS/KENOTE-091】 完全切除後のぺムブロリズマブは有意に無病生存期間を延長 - キュート先生の『肺癌勉強会』
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations - ScienceDirect
Adjuvant Pembrolizumab Approval Adds to Prevention of Recurrent NSCLC
HCP Toolkits - AIM with Immunotherapy - Immuno-Oncology Essentials
Adjuvant Immunotherapy Approved for Lung Cancer - NCI
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - The Lancet Oncology
癌免疫療法による周術期治療で呼吸器外科の治療体系は変わる(2ページ目)：日経メディカル
